Dissecting the immunogenomic biology of cancer for biomarker development

Studies have identified multiple molecular properties with a biological rationale supporting a role in mediating selective responses to immune-checkpoint inhibitors (ICIs), including loss-of-function mutations in mSWI/SNF chromatin regulators; however, their clinical biomarker relevance is uncertain...

Full description

Saved in:
Bibliographic Details
Published inNature reviews. Clinical oncology Vol. 18; no. 3; pp. 133 - 134
Main Authors Van Allen, Eliezer M, Choueiri, Toni K
Format Journal Article
LanguageEnglish
Published England Nature Publishing Group 01.03.2021
Subjects
Biology
Biomarkers
Chromatin
Genomics
Humans
Immune checkpoint inhibitors
Immune system
Immunotherapy
Mutation
Neoplasms - diagnosis
Neoplasms - genetics
Solid tumors
Online AccessGet full text
ISSN1759-4774
1759-4782
DOI10.1038/s41571-020-00461-1

Cover

More Information
Summary:Studies have identified multiple molecular properties with a biological rationale supporting a role in mediating selective responses to immune-checkpoint inhibitors (ICIs), including loss-of-function mutations in mSWI/SNF chromatin regulators; however, their clinical biomarker relevance is uncertain. Herein, we evaluate emerging concepts, challenges and considerations around translating biology into biomarkers for ICIs in solid tumours setting.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:1759-4774
1759-4782
DOI:10.1038/s41571-020-00461-1